Cannabis ingredient holds promise as antipsychotic medicine
The next steps are to carry out larger trials of CBD to confirm these initial promising findings, and to assess the effectiveness of CBD in other types of patient
Reuters (UK)
Friday, December 15, 2017
Friday, December 15, 2017
An ingredient in cannabis called cannabidiol or CBD has shown promise in a clinical trial as a potential new treatment for psychosis, scientists said. Scientists conducted a small trial of people with psychosis and found patients treated with CBD had lower levels of psychotic symptoms than those who received a placebo. Psychosis is characterized by paranoia and hallucinations. The study found that they were also more likely to be rated as “improved” by their psychiatrist and there were signs of better cognitive performance and functioning. (See also: An ingredient in cannabis may be useful for treating psychosis – new study)
tags:
